Package Leaflet: Information for the Patient
Spravato 28 mg Nasal Spray Solution
esketaamine
This medicine is subject to additional monitoring, which will allow for quick identification of new safety information. You can help by reporting any side effects you may get. The last section of section 4 will tell you how to report side effects.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
What is Spravato
Spravato contains the active substance esketamine. This belongs to a group of medicines called antidepressants and has been given to you to treat your depression.
What Spravato is used for
Spravato is used in adults to reduce symptoms of depression, such as feeling sad, anxious or useless, difficulty sleeping, changes in appetite, loss of interest in favorite activities, feeling slowed down. It is given together with another antidepressant, if you have tried at least two other antidepressants but they have not helped.
Spravato is also used in adults to quickly reduce symptoms of depression in a situation that requires immediate treatment (also known as a psychiatric emergency).
Do not use Spravato
The reason is that Spravato may cause a temporary increase in blood pressure that can cause serious complications in these conditions.
Do not use Spravato if you are in any of the above circumstances. If you are not sure, talk to your doctor before using Spravato; your doctor will decide if you can or cannot use this medicine.
Warnings and precautions
Talk to your doctor before starting to use Spravato if:
If you meet any of the above conditions (or if you are not sure), talk to your doctor before starting to use Spravato. Your doctor will decide if you should use this medicine.
Worsening of depression
Tell your doctor or go immediately to the nearest hospital if at any time you think about harming yourself or committing suicide.
It may be helpful to talk to a family member or close friend if you are depressed and ask them if they think your depression is getting worse or if they are concerned about your behavior. You can ask them to read this leaflet.
Blood pressure
Spravato may increase your blood pressure for about 1 to 2 hours after using it, so your blood pressure will be measured before you start using Spravato and after using it.
If your blood pressure is high before using this medicine, your doctor will decide if you should start using it or wait until your blood pressure is lower. If your blood pressure increases after using this medicine and remains high for more than a few hours, you may need to have some additional tests.
This medicine may cause a temporary increase in blood pressure after administering a dose. Your blood pressure will be measured before and after using this medicine. Tell your doctor immediately if you have chest pain, difficulty breathing, sudden severe headache, changes in vision or seizures (fits) after using this medicine.
Tell your doctor if you experience any of the following symptoms while using Spravato
Tell your doctor if you experience any of the above symptoms while using Spravato.
Elderly patients (> 65 years)
If you are older (> 65 years), you will be closely monitored, as you may have a higher risk of falling when you start moving after treatment.
Children and adolescents
Do not give this medicine to children or adolescents under 18 years of age. This is because Spravato has not been studied in treatment-resistant depression in this age group.
Other medicines and Spravato
Tell your doctor if you are taking, have recently taken or might take any other medicines.
Using Spravato with certain medicines may cause side effects. Tell your doctor especially if you are taking:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.
Contraceptive measures
If you can become pregnant, you should use contraceptive measures during treatment. Talk to your doctor about suitable contraceptive methods.
Pregnancy
Do not use Spravato if you are pregnant.
If you become pregnant while being treated with Spravato, talk to your doctor immediately to decide whether to stop treatment and explore other treatment options.
Breastfeeding
Do not use Spravato if you are breastfeeding. Talk to your doctor before using Spravato if you are breastfeeding. Your doctor will discuss with you whether you should stop breastfeeding or stop using this medicine. Your doctor will consider the benefit of breastfeeding for you and your baby and the benefit of treatment for you.
Driving and using machines
Spravato may make you feel drowsy, dizzy and suffer other side effects that can temporarily affect your ability to drive vehicles or use machines and perform activities that require you to be fully alert. After receiving treatment with this medicine, do not perform these activities until the day after a good night's sleep.
Follow exactly the instructions for administering this medicine given by your doctor.
In case of doubt, consult your doctor.
You will use the Spravato nasal spray yourself under the supervision of a doctor, or another healthcare professional in a healthcare setting, such as the doctor's office or clinic.
Your doctor or another healthcare professional will teach you how to use the nasal spray (see also Instructions for use).
Recommended dose
Your doctor will decide if you need 1, 2 or 3 nasal sprays and how often you should visit the doctor's office or clinic to receive the medicine.
If your treatment is continued:
During and after each use of this medicine, your doctor will check your condition and decide how long you should be monitored.
Food and drink
Some patients using Spravato may experience nausea or vomiting. You should avoid eating for 2 hours before treatment and not drink liquids for 30 minutes before using this medicine.
Nasal sprays
If you need medicines with steroids or decongestants in the form of nasal sprays, avoid using them during the hour before treatment with Spravato.
If you use more Spravato than you should
You will use this medicine under the supervision of a doctor in the doctor's office or clinic. Therefore, it is unlikely that you will use too much.
If you use too much Spravato, you are more likely to experience side effects (see “Possible side effects”).
If you stop using Spravato
It is important that you make sure to attend scheduled appointments so that this medicine is effective for you.
If you have any other questions about the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor if you notice any of the following side effects.
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist, even if they are not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and label.
The expiry date is the last day of the month stated.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Spravato Composition
The active ingredient is esketamine.
Each nasal spray device contains esketamine hydrochloride equivalent to 28 mg of esketamine.
The other ingredients are:
Citric acid monohydrate
Disodium edetate
Sodium hydroxide (for pH adjustment)
Water for injectable preparations
Product Appearance and Package Contents
Spravato is a nasal spray solution. This medication is a clear, colorless solution presented in a single-use nasal spray device.
Spravato is available in packages containing 1, 2, 3, or 6 nasal spray devices and as a multiple package containing 24 (8 packages of 3) nasal spray devices.
Each nasal spray device is individually packaged in a sealed blister.
Only some package sizes may be marketed.
Marketing Authorization Holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Manufacturer
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
You can request more information about this medication by contacting the local representative of the marketing authorization holder:
Belgium Janssen-Cilag NV Tel: +32 14 64 94 11 janssen@jacbe.jnj.com | Lithuania UAB "JOHNSON & JOHNSON" Tel: +370 5 278 68 88 lt@its.jnj.com |
Bulgaria “Johnson & Johnson” EAD Tel: +359 2 489 94 00 jjsafety@its.jnj.com | Luxembourg Janssen-Cilag NV Tel: +32 14 64 94 11 janssen@jacbe.jnj.com |
Czech Republic Janssen-Cilag s.r.o. Tel: +420 227 012 227 | Hungary Janssen-Cilag Kft. Tel: +36 1 884 2858 janssenhu@its.jnj.com |
Denmark Janssen-Cilag A/S Tel: +45 4594 8282 jacdk@its.jnj.com | Malta AM MANGION LTD Tel: +356 2397 6000 |
Germany Janssen-Cilag GmbH Tel: +49 2137 955 955 jancil@its.jnj.com | Netherlands Janssen-Cilag B.V. Tel: +31 76 711 1111 janssen@jacnl.jnj.com |
Estonia UAB "JOHNSON & JOHNSON" Estonian branch Tel: +372 617 7410 ee@its.jnj.com | Norway Janssen-Cilag AS Tel: +47 24 12 65 00 jacno@its.jnj.com |
Greece Janssen-Cilag Φαρμακευτική Α.Ε.Β.Ε. Tel: +30 210 80 90 000 | Austria Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 |
Spain Janssen-Cilag, S.A. Tel: +34 91 722 81 00 contacto@its.jnj.com | Poland Janssen-Cilag Polska Sp. z o.o. Tel: +48 22 237 60 00 |
France Janssen-Cilag Tel: 0 800 25 50 75 / +33 1 55 00 40 03 medisource@its.jnj.com | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 |
Croatia Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 jjsafety@JNJCR.JNJ.com | Romania Johnson & Johnson România SRL Tel: +40 21 207 1800 |
Ireland Janssen Sciences Ireland UC Tel: +353 1 800 709 122 | Slovenia Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 Janssen_safety_slo@its.jnj.com |
Iceland Janssen-Cilag AB c/o Vistor hf. Tel: +354 535 7000 janssen@vistor.is | Slovakia Johnson & Johnson, s.r.o. Tel: +421 232 408 400 |
Italy Janssen-Cilag SpA Tel: 800.688.777 / +39 02 2510 1 janssenita@its.jnj.com | Finland Janssen-Cilag Oy Tel: +358 207 531 300 jacfi@its.jnj.com |
Cyprus Βαρνάβας Χατζηπαναγής Λτδ Tel: +357 22 207 700 | Sweden Janssen-Cilag AB Tel: +46 8 626 50 00 jacse@its.jnj.com |
Latvia UAB "JOHNSON & JOHNSON" Latvian branch Tel: +371 678 93561 lv@its.jnj.com | United Kingdom(Northern Ireland) Janssen Sciences Ireland UC Tel: +44 1 494 567 444 |
Date of Last Revision of this Leaflet:{MM/YYYY} {Month YYYY}.
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu/.
The following information is intended for healthcare professionals only:
Instructions for Use
SPRAVATO
(esketamine)
Nasal Spray Device
28 mg per device
Each nasal spray device administers 28 mg of esketamine in two sprays.
Important
This device is intended for patient administration, under the supervision of a healthcare professional. Read these Instructions for Use carefully before training and supervising the patient.
Need Help?
If you need further assistance or would like to share your opinion, see the contact information of the local representative of the marketing authorization holder in the package leaflet.
Nasal Spray Device
Only before the first device:
Instruct the patient to blow their nose only before the first device. | |
Confirm the required number of devices. |
Instruct the patient to:
Instruct the patient to:
Instruct the patient to:
Instruct the patient to:
Instruct the patient to:
Instruct the patient to:
Instruct the patient to:
Do not blow your nose.
Reviewed: {Month YYYY}